ALPN:NSD-Alpine Immune Sciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 38.65

Change

+1.20 (+3.20)%

Market Cap

USD 2.53B

Volume

0.79M

Analyst Target

USD 21.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-0.22 (-0.06%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

-7.48 (-0.84%)

USD 106.98B
MRNA Moderna Inc

+1.79 (+1.69%)

USD 38.83B
ARGX argenx NV ADR

+4.20 (+1.14%)

USD 22.08B
BNTX BioNTech SE

+0.50 (+0.58%)

USD 21.93B
GMAB Genmab AS

+0.69 (+2.51%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-0.40 (-0.28%)

USD 18.18B
RPRX Royalty Pharma Plc

-0.11 (-0.39%)

USD 18.18B
BGNE BeiGene Ltd

+5.02 (+3.38%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-1.26 (-1.53%)

USD 16.06B

ETFs Containing ALPN

PTH Invesco DWA Healthcare Mo.. 4.42 % 0.60 %

+0.70 (+2.01%)

USD 0.15B
FYC First Trust Small Cap Gro.. 1.09 % 0.70 %

+0.75 (+2.01%)

USD 0.27B
FYX First Trust Small Cap Cor.. 0.54 % 0.63 %

+0.59 (+2.01%)

USD 0.87B
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

+0.90 (+2.01%)

USD 0.01B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

+3.79 (+2.01%)

USD 1.24B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.63 (+2.01%)

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 102.78% 89% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 102.78% 89% A- 95% A
Trailing 12 Months  
Capital Gain 378.93% 97% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 378.93% 97% N/A 99% N/A
Trailing 5 Years  
Capital Gain 463.41% 95% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 463.41% 95% A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 74.79% 89% A- 94% A
Dividend Return 74.79% 89% A- 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 131.00% 20% F 11% F
Risk Adjusted Return 57.09% 95% A 86% B+
Market Capitalization 2.53B 91% A- 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.